Photodynamic therapy for non-melanoma skin cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue 5, 2007, Pages 531-540

  Fien, Sari M ^a   Oseroff, Allan R ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Cutaneous disorders; Light based therapies; Photodynamic therapy; Skin cancer

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; ANESTHETIC AGENT; BENZOPORPHYRIN DERIVATIVE; DEFEROXAMINE; DIMETHYL SULFOXIDE; EDETIC ACID; FLUOROURACIL; PHOTOFRIN; PLACEBO; UNCLASSIFIED DRUG; VERTIPORFIN;

ACTINIC KERATOSIS; ARTICLE; B CELL LYMPHOMA; BARRETT ESOPHAGUS; BASAL CELL CARCINOMA; BLEEDING; BOWEN DISEASE; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DRUG POTENTIATION; EDEMA; ERYTHEMA; ESOPHAGUS CANCER; HUMAN; INFECTION; LIGHT; LUNG CANCER; MELANOMA; PAIN; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PIGMENTATION; RADIATION RESPONSE; SCAR FORMATION; SIDE EFFECT; SKIN CANCER; SKIN LYMPHOMA; SKIN SCAR; SKIN ULCER; UNSPECIFIED SIDE EFFECT;

EID: 34249314014     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2007.0046     Document Type: Article

References (66)

1. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
2. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992;55:145-157.
3. Fuchs J, Weber S, Kaufmann R. Genotoxic potential of porphyrin type photosensitizers with particular emphasis on 5-aminolevulinic acid: implications for clinical photodynamic therapy. Free Radic Biol Med 2000;28:537-548.
4. Jones CM, Mang T, Cooper M, et al. Photodynamic therapy in the treatment of Bowen's disease. J Am Acad Dermatol 1992;27:979-982.
5. Oseroff AR, Blumenson LR, Wilson BD, et al. A dose ranging study of photodynamic therapy with porfimer sodium (Photofrin) for treatment of basal cell carcinoma. Lasers Surg Med 2006;38:417-426.
6. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990;6:143-148.
7. Rittenhouse-Diakun K, Van Leengoed H, Morgan J, et al. The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the heme precursor delta-aminolevulinic acid (ALA). Photochem Photobiol 1995;61:523-528.
8. Szeimies RM, Kaner S. Towards a more specific therapy: targeting non-melanoma skin cancer cells. Br J Dermatol 2006;154(suppl 1):16-21.
9. Oseroff AR, Shieh S, Frawley NP, et al. Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. Arch Dermatol 2005;141:60-67.
10. Garcia-Zuazaga J, Cooper KD, Baron ED. Photodynamic therapy in dermarology: current concepts in the treatment of skin cancer. Expert Rev Anticancer Ther 2005;5:791-800.
11. Langmack K, Mehta R, Twyman P, et al. Topical photodynamic therapy at low fluence rates-theory and practice. J Photochem Photobiol B 2001;60:37-43.
12. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988;1:795-797.
13. Jeffes EW, McCullough JL, Weinstein GD, et al. Photodynamic therapy of actinic keratoses with topical aminolevulinic acid hydrochloride and fluorescent blue light. J Am Acad Dermatol 2001;45:96-104.
14. Jeffes EW. Levulan: the first approved topical photosensitizer for the treatment of actinic keratoses. J Dermatolog Treat 2002;13(suppl 1):S19-23.
15. Tschen EH, Wong DS, Pariser DM, et al. Photodynamic therapy using aminolaevulinic acid for patients with nonhyperkeratotic actinic keratoses of the face and scalp: phase IV multicentre trial with 12-month follow up. Br J Dermatol 2006;155:1262-1269.
16. Karrer S, Baumler W, Abels C, et al. Long-pulse dye laser for photodynamic therapy: investigations in vitro and in vivo. Lasers Surg Med 1999;25:51-59.
17. Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic therapy of actinic keratoses. Arch Dermatol 2003;139: 1313-1320.
18. Avram DK, Goldman MP. Effectiveness and safety of ALA-IPL in treating actinic keratoses and photodamage. J Drugs Dermatol 2004;3(suppl 1):S36-39.
19. Gold MH, Bradshaw VL, Boring MM, et al. Split-face comparison of photodynamic therapy with 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone for photodamage. Dermatol Surg 2006;32:795-801.
20. Varma S, Wilson H, Kurwa HA, et al. Bowen's disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a large-field incoherent light source. Br J Dermatol 2001;144:567-574.
21. Kurwa HA, Yong-Gee SA, Seed PT, et al. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses. J Am Acad Dermatol 1999;41:414-418.
22. Itoh Y, Ninomiya Y, Henta T, et al. Topical delta-aminolevulinic acid-based photodynamic therapy for Japanese actinic keratoses. J Dermatol 2000;27:513-518.
23. Smith S, Piacquadio D, Morhenn V, et al. Short incubation PDT versus 5-FU in treating actinic keratoses. J Drugs Dermatol 2003;2:629-635.
24. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. J Photochem Photobiol B 1995;29:53-57.
25. Fink-Puches R, Hofer A, Smolle J, et al. Primary clinical response and long-term follow-up of solar keratoses treated with topically applied 5-aminolevulinic acid and irradiation by different wave bands of light. J Photochem Photobiol B 1997;41:145-151.
26. Piacquadio DJ, Chen DM, Farber HF, et al. Photodynamic therapy with aminolevulinic acid topical solution and visible blue light in the treatment of multiple actinic keratoses of the face and scalp: investigator-blinded, phase 3, multicenter trials. Arch Dermatol 2004;140:41-46.
27. Dragieva G, Hafner J, Dummer R, et al. Topical photodynamic therapy in the treatment of actinic keratoses and Bowen's disease in transplant recipients. Transplantation 2004;77:115-121.
28. Dragieva G, Prinz BM, Hafner J, et al. A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. Br J Dermatol 2004;151:196-200.
29. Zelickson B, Counters J, Coles C, et al. Light patch: preliminary report of a novel form of blue light delivery for the treatment of actinic keratosis. Dermatol Surg 2005;31:375-378.
30. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002;47:258-262.
31. Morton C, Campbell S, Gupta G, et al. Intraindividual, right-left comparison of topical methyl aminolaevulinate-photodynamic therapy and cryotherapy in subjects with actinic keratoses: a multicentre, randomized controlled study. Br J Dermatol 2006;155:1029-1036.
32. Freeman M, Vinciullo C, Francis D, et al. A comparison of photodynamic therapy using topical methyl aminolevulinate (Metvix) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatolog Treat 2003;14:99-106.
33. Pariser DM, Lowe NJ, Stewart DM, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003;48:227-232.
34. Tarstedt M, Rosdahl I, Berne B, et al. A randomized multicenter study to compare two treatment regimens of topical methyl aminolevulinate (Metvix)-PDT in actinic keratosis of the face and scalp. Acta Derm Venereol 2005;85:424-428.
35. Fink-Puches R, Soyer HP, Hofer A, et al. Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Arch Dermatol 1998;134:821-826.
36. Morton CA, Whitehurst C, McColl JH, et al. Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Arch Dermatol 2001;137:319-324.
37. Morton CA, Whitehurst C, Moseley H, et al. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996;135:766-771.
38. Morton CA, Whitehurst C, Moore JV, et al. Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. Br J Dermatol 2000;143:767-772.
39. Salim A, Leman JA, McColl JH, et al. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. Br J Dermatol 2003;148:539-543.
40. Morton C, Horn M, Leman J, et al. Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: results of a multicenter randomized trial. Arch Dermatol 2006;142:729-735.
41. Miller S. Biology of basal cell carcinoma (part 1). J Am Acad Dermatol 1991;24:1-13.
42. Wang I, Bendsoe N, Klinteberg CA, et al. Photodynamic therapy vs. cryosurgery of basal cell carcinomas: results of a phase III clinical trial. Br J Dermatol 2001;144:832-840.
43. Svanberg K, Andersson T, Killander D, et al. Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol 1994;130:743-751.
44. Morton CA, MacKie RM, Whitehurst C, et al. Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol 1998;134:248-249.
45. Soler AM, Angell-Petersen E, Warloe T, et al. Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylenediaminetetraacetic acid: a comparison of two light sources. Photochem Photobiol 2000;71:724-729.
46. de Haas ER, Kruijt B, Sterenborg HJ, et al. Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. J Invest Dermatol 2006;126:2679-2686.
47. Fijan S, Honigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumours using delta-aminolaevulinic acid and desferoxamine. Br J Dermatol 1995;133:282-288.
48. Soler AM, Warloe T, Tausjo J, et al. Photodynamic therapy of residual or recurrent basal cell carcinoma after radiotherapy using topical 5-aminolevulinic acid or methylester aminolevulinic acid. Acta Oncol 2000;39:605-609.
49. Kennedy JC, Marcus SL, Pottier RH. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J Clin Laser Med Surg 1996;14:289-304.
50. Soler AM, Warloe T, Tausjo J, et al. Photodynamic therapy by topical aminolaevulinic acid, dimethylsulphoxide and curettage in nodular basal cell carcinoma: a one year follow-up study. Acta Derm Venereol 1999;79:204-206.
51. Thissen MR, Schroeter CA, Neumann HA. Photodynamic therapy with delta-aminolaevulinic acid for nodular basal cell carcinomas using a prior debulking technique. Br J Dermatol 2000;142: 338-339.
52. Warloe T, Heyerdahl H, Peng Q, et al. Photodynamic therapy with 5-aminolaevulinic acid induced porphyrins and skin penetration enhancer for basal cell carcinoma [abstract]. SPIE 1994;2371. Abstract 226-235. Available at http://www.spie.org/web/abstracts/2300/2371.html. Accessed March 14, 2007.
53. Choudry K, Brooke RC, Farrar W, et al. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 2003;149:124-130.
54. Soler AM, Warloe T, Berner A, et al. A follow-up study of recurrence and cosmesis in complerely responding superficial and nodular basal cell carcinoma treated with methyl 5-aminolaevulinate-based photodynamic therapy alone and with prior curettage. Br J Dermatol 2001;145:467-471.
55. Horn M, Wolf P, Wulf HC, et al. Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Br J Dermatol 2003;149:1242-1249.
56. Vinciullo C, Elliott T, Francis D, et al. Photodynamic therapy with topical methyl aminolaevulinate for 'difficult-to-treat' basal cell carcinoma. Br J Dermatol 2005;152:765-772.
57. Rhodes LE, de Rie M, Enström Y, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol 2004;140:17-23.
58. Malik Z, Ehrenberg B, Faraggi A. Inactivation of erythrocytic, lymphocytic and myelocytic leukemic cells by photoexcitation of endogenous porphyrins. J Photochem Photobiol B 1989;4:195-205
59. Paech V, Lorenzen T, Stoehr A, et al. Remission of a cutaneous mycosis fungoides after topical 5-ALA sensitisation and photodynamic therapy in a patient with advanced HIV-infection. Eur J Med Res 2002;7:477-479.
60. Leman JA, Dick DC, Morton CA. Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma. Clin Exp Dermatol 2002;27:516-518.
61. Wolf P, Fink-Puches R, Cerroni L, et al. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1994;31:678-680.
62. Orenstein A, Halik J, Tamir J, et al. Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. Dermatol Surg 2000;26:765-769.
63. Markham T, Sheahan K, Collins P. Topical 5-aminolaevulinic acid photodynamic therapy for tumour-stage mycosis fungoides. Br J Dermatol 2001;144:1262-1263.
64. Edstrom D, Porwit A, Ros A. Photodynamic therapy with topical 5-aminolevulinic acid for mycosis fungoides: clinical and histological response. Acta Derm Venereol 2001;81:184-188.
65. Coors EA, von den Driesch P. Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma. J Am Acad Dermatol 2004;50:363-367.
66. Mori M, Campolmi P, Mavilia L, et al. Topical photodynamic therapy for primary cutaneous B-cell lymphoma: a pilot study. J Am Acad Dermatol 2006;54:524-526.